FDA-ordered studies of many drugs, devices on the market are not done

The FDA has approved drugs with limited pre-market safety data contingent on postmarket studies that are frequently delayed, leaving risks and benefits unclear for patients and doctors. Policy changes reducing preapproval testing increase reliance on these delayed studies, raising concerns about patient safety and financial waste.

This Wire brief sits within Fusion42's coverage of Health: Drug Discovery.